Abstract | BACKGROUND:
Eccrine porocarcinoma (EP) is a rare malignant tumour arising in the acrosyringium, with about 50% of the cases developing local recurrence or metastatic disease. No standard therapy protocols for metastatic disease exist. In the past, only short remissions were achieved by applying combinations of cytotoxic agents, which were associated with severe side-effects. AIM OF THE STUDY: In the case reported here, the aim was to find a protocol with fewer side-effects for a patient who was not willing to undergo extensive polychemotherapy. SUBJECT: MAIN OUTCOME: This less aggressive treatment was tolerated well and the patient responded with minor remission and long-term stable disease.
|
Authors | J Gutermuth, H Audring, C Voit, U Trefzer, N Haas |
Journal | Journal of the European Academy of Dermatology and Venereology : JEADV
(J Eur Acad Dermatol Venereol)
Vol. 18
Issue 4
Pg. 477-9
(Jul 2004)
ISSN: 0926-9959 [Print] England |
PMID | 15196167
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Interferon alpha-2
- Interferon-alpha
- Recombinant Proteins
- Paclitaxel
|
Topics |
- Acrospiroma
(drug therapy, pathology)
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Humans
- Interferon alpha-2
- Interferon-alpha
(administration & dosage)
- Lymphatic Metastasis
- Male
- Paclitaxel
(administration & dosage)
- Recombinant Proteins
- Sweat Gland Neoplasms
(pathology)
|